Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.

Metabolic reprogramming has been defined as a hallmark of malignancies. Prior studies have focused on the single nucleotide polymorphism (SNP) of POLG2 gene, which is reportedly responsible for encoding mitochondrial DNA genes and is implicated in the material and energy metabolism of tumor cells, w...

Full description

Bibliographic Details
Main Authors: Chuang Wu, Huihuang Zhu, Yang Zhang, Li Ding, Junqi Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0290753&type=printable
_version_ 1797209619347537920
author Chuang Wu
Huihuang Zhu
Yang Zhang
Li Ding
Junqi Wang
author_facet Chuang Wu
Huihuang Zhu
Yang Zhang
Li Ding
Junqi Wang
author_sort Chuang Wu
collection DOAJ
description Metabolic reprogramming has been defined as a hallmark of malignancies. Prior studies have focused on the single nucleotide polymorphism (SNP) of POLG2 gene, which is reportedly responsible for encoding mitochondrial DNA genes and is implicated in the material and energy metabolism of tumor cells, whereas its function in prostate cancer has been elusive. Gene expression profile matrix and clinical information were downloaded from TCGA (The Cancer Genome Atlas) data portal, and GSE3325 and GSE8511 were retrieved from GEO (Gene Expression Omnibus) database. We conducted analysis of the relative expression of POLG2, clinical characterization, survival analysis, GO / KEGG and GSEA (Gene Set Enrichment Analysis) enrichment analysis in R and employed STRING portal to acquaint ourselves with the protein-protein interaction (PPI). IHC (Immunohistochemical) profiles of POLG2 protein between normal and cancerous tissues were consulted via HPA (Human protein atlas) database and the immunohistochemical POLG2 were verified between para-cancerous and cancerous tissues in tissue array. At the cellular level, Mitochondrial dysfunction assay, DNA synthesis test, wound healing assay, and invasion assay were implemented to further validate the phenotype of POLG2 knockdown in PCa cell lines. RT-qPCR and western blotting were routinely adopted to verify variations of molecular expression within epithelial mesenchymal transition (EMT). Results showed that POLG2 was over-expressed in most cancer types, and the over-expression of POLG2 was correlated with PCa progression and suggested poor OS (Overall Survival) and PFI (Progress Free Interval). Multivariate analysis showed that POLG2 might be an independent prognostic factor of prostate cancer. We also performed GO/KEGG, GSEA analysis, co-expression genes, and PPI, and observed the metabolism-related gene alterations in PCa. Furthermore, we verified that POLG2 knockdown had an inhibitory effect on mitochondrial function, proliferation, cell motility, and invasion, we affirmed POLG2 could affect the prognosis of advanced prostate cancer via EMT. In summary, our findings indicate that over-expressed POLG2 renders poor prognosis in advanced prostate cancer. This disadvantageous factor can serve as a potential indicator, making it possible to target mitochondrial metabolism to treat advanced prostate cancer.
first_indexed 2024-04-24T09:57:35Z
format Article
id doaj.art-4cf65a247f074dc4a1ba76c0cedabb33
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-24T09:57:35Z
publishDate 2024-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-4cf65a247f074dc4a1ba76c0cedabb332024-04-14T05:31:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-01194e029075310.1371/journal.pone.0290753Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.Chuang WuHuihuang ZhuYang ZhangLi DingJunqi WangMetabolic reprogramming has been defined as a hallmark of malignancies. Prior studies have focused on the single nucleotide polymorphism (SNP) of POLG2 gene, which is reportedly responsible for encoding mitochondrial DNA genes and is implicated in the material and energy metabolism of tumor cells, whereas its function in prostate cancer has been elusive. Gene expression profile matrix and clinical information were downloaded from TCGA (The Cancer Genome Atlas) data portal, and GSE3325 and GSE8511 were retrieved from GEO (Gene Expression Omnibus) database. We conducted analysis of the relative expression of POLG2, clinical characterization, survival analysis, GO / KEGG and GSEA (Gene Set Enrichment Analysis) enrichment analysis in R and employed STRING portal to acquaint ourselves with the protein-protein interaction (PPI). IHC (Immunohistochemical) profiles of POLG2 protein between normal and cancerous tissues were consulted via HPA (Human protein atlas) database and the immunohistochemical POLG2 were verified between para-cancerous and cancerous tissues in tissue array. At the cellular level, Mitochondrial dysfunction assay, DNA synthesis test, wound healing assay, and invasion assay were implemented to further validate the phenotype of POLG2 knockdown in PCa cell lines. RT-qPCR and western blotting were routinely adopted to verify variations of molecular expression within epithelial mesenchymal transition (EMT). Results showed that POLG2 was over-expressed in most cancer types, and the over-expression of POLG2 was correlated with PCa progression and suggested poor OS (Overall Survival) and PFI (Progress Free Interval). Multivariate analysis showed that POLG2 might be an independent prognostic factor of prostate cancer. We also performed GO/KEGG, GSEA analysis, co-expression genes, and PPI, and observed the metabolism-related gene alterations in PCa. Furthermore, we verified that POLG2 knockdown had an inhibitory effect on mitochondrial function, proliferation, cell motility, and invasion, we affirmed POLG2 could affect the prognosis of advanced prostate cancer via EMT. In summary, our findings indicate that over-expressed POLG2 renders poor prognosis in advanced prostate cancer. This disadvantageous factor can serve as a potential indicator, making it possible to target mitochondrial metabolism to treat advanced prostate cancer.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0290753&type=printable
spellingShingle Chuang Wu
Huihuang Zhu
Yang Zhang
Li Ding
Junqi Wang
Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
PLoS ONE
title Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
title_full Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
title_fullStr Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
title_full_unstemmed Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
title_short Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
title_sort interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0290753&type=printable
work_keys_str_mv AT chuangwu interferencewithmitochondrialmetabolismcouldserveasapotentialtherapeuticstrategyforadvancedprostatecancer
AT huihuangzhu interferencewithmitochondrialmetabolismcouldserveasapotentialtherapeuticstrategyforadvancedprostatecancer
AT yangzhang interferencewithmitochondrialmetabolismcouldserveasapotentialtherapeuticstrategyforadvancedprostatecancer
AT liding interferencewithmitochondrialmetabolismcouldserveasapotentialtherapeuticstrategyforadvancedprostatecancer
AT junqiwang interferencewithmitochondrialmetabolismcouldserveasapotentialtherapeuticstrategyforadvancedprostatecancer